Recursion Pharmaceuticals is laying off a fifth of its workforce in connection with a previously announced streamlining of the AI biotech’s pipeline. Shrinking the Salt Lake City-based company’s ...
In addition, Recursion is expecting early safety and PK data from a REC-1245 study in the first half of 2026. While Recursion's stock could perform extremely well long-term if the company can realize ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results